Hyperimmune immunoglobulin from human plasma vs saline placebo: Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28)
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Hyperimmune immunoglobulin from human plasma vs saline placebo Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19 Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty). Hyperimmune immunoglobulin for people with COVID‐19 (2023) · Cochrane Headline outcomes only | RR 0.72 [0.45, 1.14] | Not reported | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.